Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus (NASDAQ: EOLS) has launched its largest consumer engagement program, "Switch Your Tox and Love Evolus Forever," aimed at increasing adoption of its neurotoxin product, Jeuveau®. The campaign offers $160 off treatments for new patients at participating practices, starting September 1. This initiative includes incentives for injectors, such as product discounts and marketing support. Since its launch, Jeuveau has been administered in approximately 2 million treatments, highlighting the demand for the product in the aesthetic market.
Evolus, Inc. (NASDAQ: EOLS) has completed patient enrollment for a clinical study assessing an 'extra-strength' dosing option for its neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs). Expected interim results are due in the first half of 2023. The multicenter study involves 150 patients over 12 months and aims to evaluate the safety, efficacy, and duration of Jeuveau® at 40 units compared to existing doses. The company anticipates that this new option could meet diverse patient needs and enhance treatment customization.
Evolus (NASDAQ: EOLS) announced a post hoc analysis published in Dermatologic Surgery showcasing the effectiveness of Jeuveau® among millennials. The analysis indicated that 100% of participating millennials experienced over a 1-point improvement in the Glabellar Line Scale at days 7, 14, and 30. Additionally, 100% reported satisfaction with the treatment. Jeuveau® was well-tolerated across both millennial and non-millennial demographics, with similar adverse event rates. This study emphasizes the product's appeal within the millennial market, a crucial segment for aesthetic treatments.
Summary not available.
Evolus, a performance beauty company, announced participation in the H.C. Wainwright Global Investment Conference on May 24, 2022, from 9:00-9:30 am ET. The event aims to showcase Evolus's cutting-edge products, particularly Jeuveau®, a neurotoxin dedicated to aesthetics and FDA-approved in 2019. An audio webcast will be available on their website, with a replay for 90 days post-event. Evolus is committed to customer-centric innovation in the aesthetic market.
Evolus, Inc. (NASDAQ: EOLS) reported Q1 2022 net revenue of $33.9 million, a 177% increase from Q1 2021. The company now expects full-year revenue between $143 and $150 million, reflecting a nearly 50% year-over-year growth. Operating expenses rose to $49.4 million due to enhanced investments, while cash and equivalents stood at $106.7 million. Despite a $15.4 million operational loss, the company maintains a solid cash position to support its growth strategy and plans to launch Nuceiva® in Europe in Q3 2022.
Evolus, Inc. (NASDAQ: EOLS) will announce its first quarter 2022 financial results on May 10, 2022, after U.S. market close. Following the release, management will host a conference call at 4:30 p.m. ET for discussion, followed by a Q&A session. Investors can join via phone at (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through a live webcast on the Evolus website. A replay of the call will be available afterward. Evolus focuses on customer-centric breakthrough products in the aesthetics market, with Jeuveau® as its flagship neurotoxin.
Evolus, Inc. (NASDAQ: EOLS) has enrolled its first patient in a pivotal clinical study assessing an ‘extra-strength’ dose of Jeuveau® (prabotulinumtoxinA-xvfs), designed for aesthetic use. This multicenter, double-blind trial will involve 150 patients and compare the efficacy of 40 units of Jeuveau® against the standard 20-unit doses of Jeuveau® and BOTOX® Cosmetic. The company anticipates study completion in the first half of 2023, aiming to address a need in the aesthetic market, as clinicians have expressed interest in a stronger dosage option.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 15, 2022, from 1:35-2:00 p.m. ET. The event emphasizes Evolus’ commitment to delivering innovative products, including their FDA-approved neurotoxin, Jeuveau®, which focuses on aesthetic applications. The presentation will be accessible via an audio webcast on Evolus’ investor relations website, with a replay available for 90 days post-event.
Evolus reported Q4 2021 net revenue of $34.7 million, a 68% increase year-over-year. Full-year 2021 revenue reached $99.7 million, up 76% from 2020. The company reaffirmed guidance for 2022 revenues between $143 million and $150 million, projecting growth of 43% to 50%. Evolus added 400 new customer accounts in Q4 and achieved significant marketing successes, including over 1 billion impressions. Despite losses from operations reducing by 83%, the company is on track for growth, aiming for better profit margins post-settlement royalty reductions in September 2022.